
MoonLake CEO Sells $2.8M in Stock as Biotech Faces Clinical Setbacks
MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold $2.8M in shares, reducing holdings 4.9%. Stock down 47% year-over-year amid disappointing trial results.
MLTXhigh-risk investmentinsider selling











